Eliem Therapeutics, Inc. (ELYM)
Total Valuation
ELYM has a market cap or net worth of $91.13 million. The enterprise value is -$45.35 million.
| Market Cap | 91.13M |
| Enterprise Value | -45.35M |
Important Dates
The next earnings date is Monday, June 6, 2022, before market open.
| Estimated Earnings Date | Jun 6, 2022 |
| Ex-Dividend Date | n/a |
Share Statistics
ELYM has 26.57 million shares outstanding. The number of shares has increased by 460.40% in one year.
| Shares Outstanding | 26.57M |
| Shares Change (YoY) | +460.40% |
| Shares Change (QoQ) | -21.33% |
| Owned by Insiders (%) | 33.19% |
| Owned by Institutions (%) | 72.45% |
| Float | 2.21M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 0.55 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
| Current Ratio | 24.58 |
| Quick Ratio | 22.63 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.00 |
| Debt / FCF | 0.00 |
Financial Efficiency
Return on equity (ROE) is -83.30%, which is considered low. The company has a ROIC of -79.70%.
| Return on Equity (ROE) | -83.30% |
| Return on Assets (ROA) | -40.30% |
| Return on Capital (ROIC) | -79.70% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.41M |
| Employee Count | 37 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (1Y) | n/a |
| Total Price Change | -72.56% |
| 50-Day Moving Average | 5.50 |
| 200-Day Moving Average | 9.74 |
| Average Volume (30 Days) | 197,398 |
Short Selling Information
The latest short interest is 1.05 million, so 3.94% of the outstanding shares have been sold short.
| Short Interest | 1.05M |
| Short % of Shares Out | 3.94% |
| Short % of Float | 47.39% |
| Short Ratio (days to cover) | 3.91 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -35.67M |
| Net Income | -47.48M |
| Net Income Common | -52.03M |
| EBITDA | -47.48M |
| EBIT | -47.48M |
| Earnings Per Share (EPS) | -$2.54 |
Balance Sheet
The company has $136.48 million in cash and no debt, giving a net cash position of $136.48 million or $5.14 per share.
| Cash & Cash Equivalents | 136.48M |
| Total Debt | 0 |
| Net Cash | 136.48M |
| Net Cash Per Share | $5.14 |
| Book Value | 167.20M |
| Book Value Per Share | 6.29 |
| Working Capital | 142.22M |
Cash Flow
| Operating Cash Flow | -36.07M |
| Capital Expenditures | n/a |
| Free Cash Flow | -36.07M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ELYM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Earnings Yield | -57.09% |
| FCF Yield | -39.58% |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -460.40% |
| Shareholder Yield | -460.40% |
Analyst Forecast
The average price target for ELYM is $24.48, which is 613.70% higher than the current price. The consensus rating is "Buy".
| Price Target | $24.48 |
| Price Target Difference | 613.70% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |